In the biotechnology sector, a company’s jurisdiction directly affects its investment appeal. Being outside the USA, Europe, the UK, Canada, certain Middle Eastern countries, and China makes it nearly impossible to secure significant early-stage funding, while access to key investors, grants, and partnerships is severely limited.

The USA is the world’s largest healthcare market and a leading biotechnology hub, making relocation there, in many cases, not just advisable but critical for a company’s survival and growth. We also operate within the EU and can arrange relocation to its member states, including the UK.

NIVIRON handles the full relocation cycle — from intellectual property transfer to team relocation — ensuring the company is established in a jurisdiction where capital, infrastructure, and strategic partners are concentrated.

As part of this task, we:

• Organize intellectual property transfer — re-registration of rights, filing in new jurisdictions, and preparation for international patent procedures;
• Relocate the team and their families — visa support (O-1, EB-1A, E-2, Global Talent, Innovator Founder, EU startup visas), housing, education, and healthcare assistance;
• Create a legally compliant corporate structure — aligned with the requirements of investors, grant providers, and regulators, including export control and sanctions compliance;
• Integrate the company into the new business ecosystem — connecting to industry communities, accelerators, and partner networks.

Result: relocating to the USA or EU opens access to the largest markets and capital sources, accelerates fundraising, and increases the chances of successful technology commercialization.